SS-31 50mg

SS-31 50mg

Tetrapeptide cardiolipin · Mitochondrial function · Research Only

What is it and how does it work?

SS-31 (Elamipretide / MTP-131 / Bendavia) is an aromatic-cationic tetrapeptide (D-Arg-DMT-Lys-Phe-NH2) developed by Szeto and Schiller. Mechanistic literature documents that it crosses the outer mitochondrial membrane and selectively binds to cardiolipin in the inner membrane (Szeto HH, Br J Pharmacol 2014, PMID 23647488), with stabilization of respiratory chain supercomplexes (I, III, IV), preservation of ATP synthase, reduction of electron leak, and decrease in ROS without collapse of the ΔΨm potential in experimental models.

Clinical research evidence: Karaa et al. (Neurology 2018, PMID 30568002) in primary mitochondrial myopathy. Daubert et al. (Circ Heart Fail 2017, PMID 29217757) in exploratory heart failure. Stealth BioTherapeutics trial program — PROGRESS-HF, MMPOWER-3, TAZPOWER (Barth syndrome), ReCLAIM (dry AMD/geographic atrophy) — validated SubQ 40 mg/day safety in research with positive signals on secondary endpoints. Research material only — no FDA-approved human use.

Reconstitution and dosage

• Vial 50 mg lyophilized
• Bacteriostatic water: 2 ml (tablet — standard rule would be 10 ml, doesn't fit in 3ml vial)
• Resulting concentration: 25,000 mcg/ml = 25 mg/ml
• Per unit U-100: 250 mcg · verification: 25,000 ÷ 100 = 250 mcg/u ✓
• Conservation Refrigerated 2–8°C · Use within 28–30 days · Protect from light (photosensitive) · DO NOT FREEZE reconstituted
• Performance Equivalent volume: 200 U-100 units per reconstituted vial

Volume Conversion Chart (U-100 syringe)

Documented evidence in research literature

Combinations reported in literature

• SS-31 + MOTS-C: Complementary Mitochondrial Mechanisms in the Literature — MOTS-C Metabolic Signaling (AMPK) + SS-31 Mitochondrial Structural Preservation.
• SS-31 + NAD+ (injectable or oral NMN/NR): Literature reports complementarity — NAD+ substrate of complex I/sirtuins; SS-31 protects mitochondrial machinery.
• SS-31 + Urolithin A oral: Emerging Literature — Urolithin Induces Mitophagy (Replacement of Damaged Mitochondria); SS-31 Protects Functional Ones.
• SS-31 + CJC/Ipamorelin: Literature reports independent axes — GH/IGF-1 (tissue recovery) + SS-31 (mitochondrial oxidative capacity).

Practical notes

• Via documented in primary research literature: SubQ. Stealth BioTherapeutics validated SubQ 40 mg/day in all phase III trials. Large peptide (640 Da) highly cationic — not absorbed orally/sublingually/intranasally at comparable doses.
• Reconstitution compressed to 2 ml (standard rule would give 10 ml, does not fit in 3 ml vial). Concentration 250 mcg/u — mental scale equivalent to GHK-Cu.
• Response window documented in clinical literature: functional markers (6MWT, VO2, subjective energy) at weeks 4-8. Structural markers (echo, GLS) require 12+ weeks.

Contraindications and precautions

• For research use only. Not approved by the FDA for human use. The literature documents local reactions (erythema, pruritus, induration) in ~30–50% of subjects receiving 40 mg/day in the MMPOWER-3 and ReCLAIM studies. Not for human use. Do not mix in the same syringe with anionic peptides (Thymosin Beta-4)—precipitation has been reported in the literature.

Research material only. Not approved for human use by the FDA. This product is intended for scientific research purposes in controlled laboratory settings only. It is not a drug. Not for human or animal administration, therapeutic use, or diagnostic use.